A5090392559- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Antibiotics Pharmacokinetics and Efficacy
- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Pharmaceutical studies and practices
- Chronic Myeloid Leukemia Treatments
- T-cell and B-cell Immunology
- Biosimilars and Bioanalytical Methods
- Tuberculosis Research and Epidemiology
- Antibiotic Use and Resistance
- Antimicrobial Resistance in Staphylococcus
- Burn Injury Management and Outcomes
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Wound Healing and Treatments
- Pneumonia and Respiratory Infections
- Lymphoma Diagnosis and Treatment
- Injury Epidemiology and Prevention
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Blood disorders and treatments
- Urticaria and Related Conditions
- Pregnancy and Medication Impact
The University of Texas MD Anderson Cancer Center
2017-2020
Kerala Institute of Medical Sciences
2009-2019
Sultan Ismail Specialist Hospital
2019
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2017
University of Milan
2017
Leiden University Medical Center
2017
Health Action by People
2014
St.John's Medical College Hospital
2013
University Hospital Heidelberg
2012
Heidelberg University
2012
The development of neutralizing anti–factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy.
To assess the effects of B lymphocyte stimulator (BLyS)-specific inhibitor belimumab on immunologic biomarkers, including cell and T populations, maintenance antibody titers to prior vaccines in autoantibody-positive systemic lupus erythematosus (SLE) patients.Pooled data from 2 phase III trials, Study Belimumab Subjects with SLE 52-week (BLISS-52) 76-week (BLISS-76) comparing 1 mg/kg or 10 versus placebo (plus standard therapy for each group) were analyzed changes autoantibody,...
Safety data were pooled and analyzed from one phase 2 two 3 double-blind, placebo-controlled, repeat-dose systemic lupus erythematosus (SLE) trials of belimumab 1, 4 (phase only), 10 mg/kg. Types rates adverse events (AEs) similar across treatment groups. Rates patients experiencing any serious AE 16.6%, 19.5%, 13.5%, 18.0% with placebo, 4, mg/kg, respectively; infusion reactions (including hypersensitivity reactions) occurring on the same days as infusions 0.4%, 0.9%, 0%, infections 5.5%,...
This extension study of the Phase III, randomized, placebo-controlled Belimumab International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with to continue belimumab treatment, in order evaluate its long-term safety tolerability including organ damage accrual.
Majority burn mortality prognostic scores were developed and validated in western populations. The primary objective of this study was to evaluate identify possible risk factors which may be used predict burns a local Malaysian intensive care unit. secondary validate the five well known (Baux score, Abbreviated Burn Severity Index (ABSI) Ryan Belgium Outcome Injury (BOBI) score revised Baux score) prediction.Patients that treated at Hospital Sultan Ismail's Burns Intensive Care (BICU) unit...
Prognostic measures to determine burn mortality are essential in evaluating the severity of individual victims. This is an important process triaging patients with high risk that may be nursed acute care setting. Malaysian research lacking only one publication identified which describes epidemiology Therefore, objective this study was go step further and identify predictors from a burns intensive unit (BICU) used triage at higher death.This retrospective cohort all admissions Hospital Sultan...
To evaluate the palatability, cost and other compliance issues as variables in selection of antibiotic suspensions for children.Eighty-six physicians health care personnel randomly sampled amoxicillin (used a standard comparison) 11 antibiotics, evaluating them categories appearance, smell, texture, taste aftertaste. Overall scoring was then adjusted cost, duration therapy dosing intervals.Overall (palatability) ranking highest to lowest, follows: loracarbef, cefdinir, cefixime,...
This study examined the palatability of 22 antimicrobial suspensions by using five independent categories for scoring: appearance, smell, texture, taste, and aftertaste. The likely overall influence on patient compliance was also evaluated. Drugs were compared within their respective classes. only antibiotics judged to be so unpalatable as potentiallyjeopardize dicloxacillin, oxacillin, erythromycin/sulfisoxazole, cefpodoxime. Among penicillins, amoxicillin ampicillin preferred. Azithromycin...
The aim was to study the feto-maternal outcome of pregnancies complicated by systemic lupus erythematosus (SLE). Analysis a prospectively-maintained database 73 patients (June 2006–March 2016) done. Diagnosis SLE made ACR(American College Rheumatology)-criteria. Protocol scans and blood tests were done with active disease followed biweekly for 28 weeks, weekly thereafter. Mean age + SD 29 ± 4.9. diagnosed before conception in 86% patients. A total 33% had status during pregnancy out them 58%...
<h3>Background</h3> Comparative effectiveness trials using suitable endpoints are necessary to demonstrate therapeutic equivalence of biosimilar molecules. <h3>Objectives</h3> This phase 3 double-blind, active comparator, clinical trial compared the efficacy and safety a infliximab (IFX), BOW015, innovator IFX (iIFX). <h3>Methods</h3> 189 subjects with rheumatoid arthritis (RA) diagnosed according 2010 ACR/EULAR criteria, on stable doses oral methotrexate (MTX) 10-20 mg/wk, were randomized...
Introduction: Osteoporosis is a serious condition affecting up to 50% of Indian postmenopausal women. Denosumab reduces bone resorption by targeting the receptor activator nuclear factor-κB ligand. This study assessed efficacy and safety denosumab in women with osteoporosis. Materials Methods: In this double-blind, multicenter, phase 3 study, 250 aged 55 75 years (T-score <-2.5 >-4.0 at lumbar spine or total hip; serum 25(OH) D levels ≥20 ng/mL) were randomized receive one subcutaneous dose...
To evaluate the palatability and cost as variables in selection of antimicrobial suspensions to treat staphylococcal infections oral thrush, 31 physicians health care personnel randomly sampled 7 antistaphylococcal antibiotics 2 antifungal agents, evaluating them categories appearance, smell, texture, taste, aftertaste. Final scoring was then adjusted for cost. Overall taste (palatability) ranking antibiotics, highest lowest, follows: rifampin, cephalexin, EES, TMP/SMX, clindamycin with...
Gangrene is an uncommon complication in cases of rickettsial spotted fever. We report three fever from south India, presumably caused by Rickettsia conorii subspecies indica. Along with gangrene, these had severe manifestations sepsis and multiorgan dysfunction syndrome (MODS) like acute kidney injury, liver dysfunction, delirium seizure. One patient died while the other two recovered well. This case series being reported to highlight occurrence gangrene rickettsiosis importance appropriate...
The necessity for routine monitoring of serum vancomycin concentrations (SVCs) has recently come under intense review at many institutions, including our own, not just because cost issues related to this frequently used antibiotic but original concerns nephrotoxicity have been largely alleviated. Many experts currently do recommend measurement SVCs in patients with normal renal function who are treated the usual dosages vancomycin,1-3 whereas others continue firmly support monitoring.4 Early...
Many patients with hypertension will require multiple antihypertensive drugs to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combinations (SPCs) in mild-to-moderate who were non-responsive aliskiren monotherapy. After a 4-week run-in 300 mg, mean sitting diastolic BP (msDBP) ≥ 90 <110 mmHg randomized oncedaily aliskiren/ amlodipine 300/10 mg or 300/5 for 8 weeks. Aliskiren/amlodipine SPCs provided...
<h3>Background</h3> BOW015 is being developed as a biosimilar of reference infliximab (rIFX, Remicade®). Therapeutic equivalence and rIFX was evaluated in patients with active rheumatoid arthritis (RA) 54-week (wk) Phase 3 comparative effectiveness study. ACR20 responses safety immunogenicity data have been reported.<sup>1,2</sup> Here, we report the secondary efficacy endpoints for this <h3>Objectives</h3> To determine whether equivalent to that when each administered combination...
<h3>Background</h3> Blisibimod, a potent inhibitor of B cell activating factor (BAFF), was evaluated in Phase 2b clinical trial patients with SLE. <h3>Objectives</h3> To determine the effect subcutaneous blisibimod on SLE disease activity, including rate response to responder index (SRI). <h3>Methods</h3> 547 serologically-active baseline SELENA-SLEDAI ≥6 were randomized receive (100mg weekly (QW), 200mg QW, or Q4W) placebo matchin dosing regimens. The primary endpoint comparison at Week 24...
Background: Metabolic acidosis is a common abnormality in the intensive care unit. There has recently been surge of interest nontraditional approaches to analysis acid base disorders.Aims and Objectives: This study was undertaken compare application physicochemical method Stewart traditional Henderson-Hasselbach equation withcorrection for albumin quantification disorders.Materials Methods: All patients with metabolic admitted ICU as defined by deficit >2.5 were included study. The APACHE...